We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Molecular Mechanism Identified That Enables Leukemia Cells to Evade Chemotherapy

By LabMedica International staff writers
Posted on 01 Feb 2012
Cancer researchers have identified a molecular mechanism used by acute myeloid leukemia (AML) cells to evade chemotherapy.

Investigators at the University of Colorado School of Medicine (Denver, USA) used novel molecular and computational approaches to perform genome-wide short-hairpin RNA screens to identify proteins that mediate the fate of AML cells after exposure to the drug cytarabine (cytosine arabinoside). More...
Gene expression profiling of AML cells exposed to cytarabine was carried out to identify genes with expression induced by the drug treatment. Such gene activity was compared to records of gene expression data from primary patient samples.

Results published in the January 13, 2012, online edition of the journal Leukemia strongly implicated cell-cycle checkpoint proteins, particularly WEE1, as critical mediators of AML cell survival after cytarabine exposure. Knockdown of WEE1 in a secondary screen confirmed its role in AML cell survival. Pharmacologic inhibition of WEE1 in AML cell lines and primary cells increased the potency of cytarabine.

Wee1 inhibits entry of cells into mitosis, and its absence leads to division at a premature stage and sub-normal cell size. Conversely, when Wee1 expression is increased, mitosis is delayed and cells grow to a large size before dividing. Further experiments conducted as part of the current study demonstrated that inhibition of WEE1 prevented S-phase arrest in AML cells induced by cytarabine, broadening the functions of WEE1 that may be exploited therapeutically.

“Introducing chemotherapy to cells is like putting a curve in front of a speeding car,” said first author Dr. Christopher Porter, assistant professor of pediatrics at the University of Colorado School of Medicine. “Cells that can put on the brakes make it around the corner and cells that cannot speed off the track. WEE1 is the brakes. With chemotherapy, we introduce DNA damage in cancer cells – we push them toward the curve hopefully at a greater rate than healthy cells. If WEE1 is there, cancer cells can round the curve. Without it, they flip.”

“I am optimistic that this will eventually lead to a therapeutic regimen that allows us to target AML cells that have escaped conventional therapies,” said Dr. Porter. “In light of
these data, we are already early in the clinical trial planning process.”

Related Links:

University of Colorado School of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.